EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025.04.02

Essex Bio-Technology Reports Stellar 2024 Annual Results：Net Profit soars 11.6% to HK$ 307.2 Million, Dividend increases 33.3% Focuses on Strengthening R&D Capabilities and Expanding Market Access

2025.03.26

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Date

Title

2021-04-20

Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia

2021-04-07

Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China

2021-03-19

Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD

2021-03-12

Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half

2021-02-24

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2020-11-23

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-10-15

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT